Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2008
03/19/2008EP1900370A1 Composition for repairing nerve damage
03/19/2008EP1900367A2 Hypoglycemic agent
03/19/2008EP1900366A2 Hypoglycemic agent
03/19/2008EP1900364A2 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
03/19/2008EP1900361A1 Solution for canal irrigation based on sodium hypochlorite and proteolytic enzyme
03/19/2008EP1899475A2 A composition for wound healing and use thereof
03/19/2008EP1899456A2 Methods for tissue engineering
03/19/2008EP1899372A1 Composition and method for producing stable amyloid beta oligomers of high molecular weight
03/19/2008EP1899367A1 Mutant allergen(s)
03/19/2008EP1899365A2 Angiotensin i-converting enzyme (ace) inhibitors
03/19/2008EP1899363A1 Method for identifying modulators of rufy2 useful for treating alzheimer's disease
03/19/2008EP1898945A2 Airway administration of site-inactivated fviia in inflammatory conditions affecting the respiratory tract
03/19/2008EP1898944A2 Effect of bri proteins on abeta production
03/19/2008EP1898943A2 Cxcr4 antagonists for wound healing and re-epithelialization
03/19/2008EP1898941A2 Controlled-release formulation useful for treating disorders associated with hepatitis c virus
03/19/2008EP1898940A1 Inhibitors of the alpha2beta 1/gpia-iia integrin
03/19/2008EP1898939A2 Compositions and methods for less immunogenic pr0tein-lip1d complexes
03/19/2008EP1898938A2 Liquid protein markers for native gel electrophoresis
03/19/2008EP1898931A2 Glucose uptake modulator and method for treating diabetes or diabetic complications
03/19/2008EP1898883A2 Complexation of metal ions with polypeptides
03/19/2008EP1898692A2 Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
03/19/2008EP1711174B1 Adjuvant compositions
03/19/2008EP1610803A4 Methods and kits for maintaining pregnancy, treating follicular cysts, and synchronizing ovulation using luteinizing hormone
03/19/2008EP1575991A4 Peptides comprising aromatic d-amino acids and methods of use
03/19/2008EP1513545B1 Methods and means to promote gut absorption
03/19/2008EP1428880B1 Kidney-specific urate transporter and gene thereof
03/19/2008EP1362031B1 Pharmaceutically active piperidine derivatives
03/19/2008EP1326980B1 Methods of treatment using wisp polypeptides
03/19/2008EP1282437B1 Treatment of cartilage disorders
03/19/2008EP1232753B1 Stable protein solution filled in a container made from a hydrophobic resin and method of stabilizing the same
03/19/2008EP1200137B1 Agent for occluding blood vessels
03/19/2008EP1043328B1 Novel physiologically active substance sulphostin, process for producing the same, and use thereof
03/19/2008EP1012240B1 Cancer immunotherapy with semi-allogeneic cells
03/19/2008EP1009831B1 Agonist antibodies to the thrombopoietin receptor, and their therapeutic uses
03/19/2008EP0980240B1 Sustained-release compositions and method for preparing same
03/19/2008EP0979279B1 Hemoglobin mutants with reduced nitric oxide scavenging
03/19/2008EP0910647B1 Human dnase i hyperactive variants
03/19/2008EP0652766B2 Human growth hormone aqueous formulation
03/19/2008EP0594669B9 Growth factor-responsive neural progenitor cells which can be proliferated in vitro.
03/19/2008CN101146908A Novel protease, microorganism producing the same, and application thereof
03/19/2008CN101146826A FC-fusion constructs binding to phosphatidylserine and their therapeutic use
03/19/2008CN101146825A A molecule and chimeric molecules thereof
03/19/2008CN101146823A Molecules and chimeric molecules thereof
03/19/2008CN101146822A EphB receptor-binding peptides
03/19/2008CN101146819A Peptides that increase collagen or hyaluronic acid production
03/19/2008CN101146552A Therapy of prostate cancer with CTLA4 antibodies and hormonal therapy
03/19/2008CN101146549A Antiangiogenic agents and aldesleukin
03/19/2008CN101146548A Methods for treating lymphomas using a combination of a chemotherapeutic agent and IL-2 and optionally an anti-CD20 antibody
03/19/2008CN101146547A Use of myostatin (GDF-8) antagonists for improving wound healing and preventif fibrotic disease
03/19/2008CN101146546A Muscle regeneration
03/19/2008CN101146545A Mucin hypersecretion inhibitors based on the structure of MANS and methods of use
03/19/2008CN101146532A Pharmaceutical compounds
03/19/2008CN101144082A Recombination human ciliary neurotrophy factor, mutant and application thereof
03/19/2008CN101144081A Nucleic acid molecule TRAIL and application in preparation of anti-tumour pharmaceutical
03/19/2008CN101144061A Yeast engineering bacterium for producing human pepsinogen and its preparation method and application
03/19/2008CN101143902A Anti-HER2 single-chain antibody-cefuroxime sodium enhanced fusion protein HER2(Fv-LDM)
03/19/2008CN101143901A Application of fusion protein GST-PTD-SOD in radioresistance
03/19/2008CN101143898A Treatment of allergic conditions by use of IL-21
03/19/2008CN101143894A Highly effective polypeptide for inhibiting angiogenesis, physical chemistry modifying method and application thereof
03/19/2008CN101143893A Thymus tripeptide active isomer and preparation method and medical use thereof
03/19/2008CN101143892A 丙型肝炎三肽抑制剂 Tripeptide inhibitor of hepatitis C
03/19/2008CN101143890A New born calf brain active peptide, preparation method and application thereof in preparing anti-cancer medicament
03/19/2008CN101143855A Method for synthesizing esters of n-[(s)-1-carboxybutyl]-(s)-alanine and use thereof for synthesizing perindopril
03/19/2008CN101143222A Application of p53 expression product in preparing medicine for treating tumor
03/19/2008CN101143221A Central airway administration for systemic delivery of therapeutics
03/19/2008CN101143217A Treatment of neurological and neuropsychological disorders
03/19/2008CN101143215A Proteinase inhibitor nervous cell protecting function and application
03/19/2008CN101143214A Important regulating gene RPS6KA2 for IL-2RG signal pathway
03/19/2008CN101143213A Male analeptic and preparing process thereof
03/19/2008CN101143212A Recombination human acidic mechanocyte growth factor temperature sensitive type gel preparation and preparation method thereof
03/19/2008CN101143211A Method for producing heatproof human fiber collagen
03/19/2008CN101143210A Compound fatty milk oral preparation
03/19/2008CN101143209A Application of KILLER polypeptide in preparing medicine for treating tumor
03/19/2008CN101143208A Sobering-up liver-protecting capsule and production method thereof
03/19/2008CN101143207A Application of natural type, breaking type or No. 5 domain delation variant type beta 2 glycoprotein I in preparing medicine for inhibiting blood vessel newborn
03/19/2008CN101143131A Method for preparing human insulin inhaled dry powder using with supercritical fluid technology
03/19/2008CN100375750C Oligopolynucleotide of inhibiting activity of necrosin in human tumor
03/18/2008US7345158 Cardiac failure, cardiomegaly, myocarditis, cardiomyopathy, arteriosclerosis, arteriosclerosis obliterans, or ischemic heart disease
03/18/2008US7345154 growth hormone supergene family; prolongs circulating half-lives of protein therapeutics in the body so proteins do not have to be injected frequently; adding cysteine residues to non-essential regions using site-directed mutagenesis; covalently coupling a cysteine-reactive polymer via the added cysteine
03/18/2008US7345153 An antibody capable of specifically inhibiting the fusion of an HIV-1 envelope glycoprotein cell with a CD4+ cell without cross reacting with the HIV-1 envelope glycoprotein or CD4 and inhibits infection by strains of HIV-1
03/18/2008US7345151 Antagonists specific for denatured collagen and methods of using same
03/18/2008US7345150 Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
03/18/2008US7345149 growth hormone supergene family; prolongs circulating half-lives of protein therapeutics in the body so proteins do not have to be injected frequently; adding cysteine residues to non-essential regions using site-directed mutagenesis; covalently coupling a cysteine-reactive polymer via the added cysteine
03/18/2008US7345148 Human G-protein coupled receptor, HGPRBMY29sv1 polypeptides
03/18/2008US7345146 PRO1271 Polypeptides
03/18/2008US7345144 Melanocortin receptor-specific hexapeptides
03/18/2008US7345142 Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease
03/18/2008US7345093 Methods of enhancing solubility of compounds
03/18/2008US7345081 Azabicyclo-octane inhibitors of IAP
03/18/2008US7345039 Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
03/18/2008US7345027 Controlling gene expression using RNA preferential for endothelial growth factor genes and transmembrane tyrosine kinases; antiproliferative agents
03/18/2008US7345025 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
03/18/2008US7345022 Anti-fibril peptides
03/18/2008US7345021 Method for PR-39 peptide regulated stimulation of angiogenesis
03/18/2008US7345020 Macrocyclic peptidomimetic for use in treatment of multiple sclerosis and autoimmune disorders
03/18/2008US7345019 Modulation of excitable tissue function by peripherally administered erythropoietin
03/18/2008US7345018 Immobilization drug; side effect reduction
03/18/2008US7344884 Fibronectins; fibroblast growth factors
03/18/2008US7344879 Peptide for use in the treatment of cell proliferation disorders
03/18/2008US7344872 involves engineering a recombinant shuttle vector comprising a nucleic acid cassette encoding prokaryotic green fluorescent protein (GFP) operably linked to regulatory sequences which permit its expression in a host cell
1 ... 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 ... 3163